Hsbc Holdings PLC Acquires 979 Shares of Repligen Co. (NASDAQ:RGEN)

Hsbc Holdings PLC raised its holdings in Repligen Co. (NASDAQ:RGENFree Report) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,102 shares of the biotechnology company’s stock after buying an additional 979 shares during the quarter. Hsbc Holdings PLC’s holdings in Repligen were worth $1,458,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in RGEN. WealthPlan Investment Management LLC bought a new stake in shares of Repligen in the 3rd quarter worth about $210,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Repligen during the 3rd quarter worth about $413,000. Charles Schwab Investment Management Inc. grew its holdings in Repligen by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 326,667 shares of the biotechnology company’s stock worth $51,943,000 after acquiring an additional 8,667 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Repligen by 10.0% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 3,353 shares of the biotechnology company’s stock worth $533,000 after acquiring an additional 304 shares during the last quarter. Finally, Pathstone Family Office LLC grew its holdings in Repligen by 38.0% during the 3rd quarter. Pathstone Family Office LLC now owns 5,641 shares of the biotechnology company’s stock worth $897,000 after acquiring an additional 1,554 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

RGEN has been the topic of a number of research analyst reports. KeyCorp increased their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Read Our Latest Stock Analysis on RGEN

Insider Activity at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $145.78 on Friday. The company has a market capitalization of $8.15 billion, a price-to-earnings ratio of 583.14, a P/E/G ratio of 4.96 and a beta of 1.04. The firm’s 50 day simple moving average is $164.74 and its 200 day simple moving average is $177.29. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGENGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.64 earnings per share. As a group, sell-side analysts forecast that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.